Semperit (SEM) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
13 May, 2026Executive summary
Q1 2026 saw strong operational recovery and momentum from H2 2025, with both divisions contributing to performance.
Revenue grew 7.9% year-over-year to EUR 163.7 million, EBITDA more than doubled to EUR 26.8 million, margin at 16.4%.
Focused execution of strategic priorities, cost savings, and innovation initiatives supported results.
Digital transformation advanced with onboarding of new entities and oneERP initiatives.
Earnings after tax improved to EUR 8.9 million from a loss of EUR -7.2 million in Q1 2025.
Financial highlights
Revenues rose to EUR 164 million (up 8% year-on-year); EBITDA more than doubled to EUR 27 million, margin up to 16.4%.
EBIT improved to EUR 14.4 million from EUR -1.3 million; earnings after tax reached EUR 8.9 million.
Free cash flow increased to EUR 13.1 million, with disciplined CapEx at EUR 7.7 million.
Net financial debt reduced to EUR 81.9 million, leverage ratio at 0.9x; cash and cash equivalents at EUR 101.8 million.
Equity ratio stable at 48.2%.
Outlook and guidance
Full-year 2026 guidance confirmed: high single-digit revenue growth and operating EBITDA around EUR 95 million (before EUR 5 million project costs).
CAPEX for 2026 expected at EUR 50 million (EUR 35 million maintenance, EUR 15 million strategic growth).
Project expenses for oneERP expected at approx. EUR 5 million (P&L effective).
Mid-term growth drivers include German infrastructure, EU defense spending, and Ukraine reconstruction.
Ongoing geopolitical and macroeconomic uncertainties, especially regarding raw material costs and demand.
Latest events from Semperit
- Margin recovery, innovation, and sustainability drive a strong 2026 growth outlook.SEM
Austrian Select Conference23 Apr 2026 - Operating EBITDA beat guidance and margin rebounded; 2026 targets growth and higher profitability.SEM
Q4 202518 Mar 2026 - EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 20241 Feb 2026 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 202416 Jan 2026 - EBITDA up 21%, earnings positive, and free cash flow nearly doubled despite weak demand.SEM
Q4 202424 Dec 2025 - Q3 2025 profit turnaround and strong order intake support a confident full-year EBITDA outlook.SEM
Q3 202517 Dec 2025 - Q1 2025 saw steep profit declines, improved cash flow, and cautious optimism for H2 recovery.SEM
Q1 202526 Nov 2025 - Q2 recovery lifted order intake and margins; full-year EBITDA guidance and CapEx confirmed.SEM
Q2 202523 Nov 2025